With its recent outperformance, the ETF is now poised to retest its key resistance level near $160. Investors will want to watch XLV closely, as a surge past$160 could signal a new era of momentum and outperformance for the sector.From a technical perspective, the healthcare ETF could be on the verge of an impressive breakout.Offering a 1.55% dividend yield and exposure to leading companies like Johnson & Johnson, UnitedHealth Group (NYSE: UNH), and Amgen (NASDAQ: AMGN), the XLV captures a broad swath of t ...